Fresh off its victory at the Slush 100 competition, where it secured a €1 million equity investment from General Catalyst and Cherry Ventures, Delft-based startup OASYS NOW has announced its partnership with Progress Clinical Research.
The collaboration aims to accelerate patient recruitment for clinical drug trials in the Netherlands, leveraging OASYS NOW’s AI to streamline the process and reduce barriers to life-saving treatments.
OASYS NOW CEO Nima Salami reflected on the impact of the partnership: “Our collaboration with Progress Clinical Research is a significant step towards a future where personalised medicine is a reality for everyone. By streamlining clinical trials and accelerating research, we’re paving the way for more targeted and effective treatments for a variety of diseases. We are confident that our collaboration with Progress Clinical Research will have a profound impact on the lives of patients and contribute to a future where diseases are no longer a threat.”
OASYS NOW, a Delft-based AI and cybersecurity startup, specialises in healthcare and life sciences. Its AI-powered platform, ELaiGIBLE, is designed to further clinical trials by automating the identification of eligible patients from electronic health records.
The technology extracts and categorises eligibility criteria from trial protocols, generating a prioritised list of candidates with matching scores and supporting documentation.
This innovation reduces the time, cost, and inefficiencies of traditional patient recruitment processes, a critical bottleneck in clinical research.
The partnership will see ELaiGIBLE integrated into Progress Clinical Research’s operations, reportedly reducing screen failures by a significant amount and improve the success rates of clinal trials.
Established in 2009 and operating trial sites in Amsterdam, Den Bosch, and Zwolle under the Brain Research Center brand, Progress Clinical Research focuses on central nervous system, cardiometabolic, and immune diseases. The company connects patients, pharmaceutical firms, and healthcare professionals to advance treatments for conditions with high unmet medical needs.
“This collaboration marks a significant step forward in our mission to increase health through accelerating the development of breakthrough treatments for a range of diseases where there is a high unmet need for patients,” says Niels Prins, CEO of Progress Clinical Research. “ELaiGIBLE’s ability to efficiently identify eligible patients will empower us to expedite our clinical trials and bring new hope to patients and their families.”
Read the orginal article: https://www.eu-startups.com/2024/12/oasys-now-turns-slush-victory-into-action-with-clinical-trial-partnership/
